Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBIO
2676
Crescent Biopharma
CBIO
$637M
| $779K | ﹤0.01% |
2,570
-2,693
| -51% | -$397K |
|
2677
Hycroft Mining Holding Corp
HYMC
$2.52B
| $777K | ﹤0.01% |
146,090
-77,490
| -35% | -$495K |
|
2678
MediWound
MDWD
$174M
| $776K | ﹤0.01% |
57,544
-3,462
| -6% | -$35K |
|
|
OPTU
2679
Optimum Communications Inc
OPTU
$251M
| $775K | ﹤0.01% |
168,400
-30,100
| -15% | -$148K |
|
2680
Invesco CurrencyShares Japanese Yen Trust
FXY
$426M
| $775K | ﹤0.01% |
10,900
+5,970
| +121% | +$395K |
|
2681
Vanguard Morningstar Mega Cap Growth ETF
MGK
$33.9B
| $774K | ﹤0.01% |
22,500
+1,000
| +5% | +$35.8K |
|
|
GES
2682
DELISTED
Guess Inc
GES
| $772K | ﹤0.01% |
+37,300
| New | +$686K |
|
2683
Vanguard Morningstar Mid-Cap Value ETF
VOE
$24.6B
| $771K | ﹤0.01% |
5,700
-8,400
| -60% | -$1.13M |
|
2684
Essential Properties Realty Trust
EPRT
$6.72B
| $770K | ﹤0.01% |
32,800
-159,200
| -83% | -$3.47M |
|
2685
Schwab International Small-Cap Equity ETF
SCHC
$5.71B
| $768K | ﹤0.01% |
24,400
+200
| +0.8% | +$6.09K |
|
|
NM
2686
DELISTED
Navios Maritime Holdings Inc.
NM
| $766K | ﹤0.01% |
437,870
-128,944
| -23% | -$247K |
|
2687
ImmuCell
ICCC
$90.9M
| $765K | ﹤0.01% |
125,489
-12,097
| -9% | -$87.3K |
|
2688
GEE Group
JOB
$27M
| $762K | ﹤0.01% |
1,554,900
+442,300
| +40% | +$297K |
|
2689
Virco
VIRC
$95.2M
| $762K | ﹤0.01% |
168,630
+5,902
| +4% | +$24.9K |
|
2690
Relmada Therapeutics
RLMD
$512M
| $760K | ﹤0.01% |
+217,810
| New | +$1.91M |
|
|
AIOT
2691
PowerFleet Inc
AIOT
$417M
| $758K | ﹤0.01% |
281,910
-16,239
| -5% | -$44.5K |
|
2692
iShares MSCI Sweden ETF
EWD
$587M
| $757K | ﹤0.01% |
+23,400
| New | +$731K |
|
2693
iShares MSCI Italy ETF
EWI
$1.08B
| $757K | ﹤0.01% |
+28,100
| New | +$716K |
|
2694
Meridian
MRBK
$240M
| $757K | ﹤0.01% |
49,956
+7,166
| +17% | +$114K |
|
2695
The ONE Group
STKS
$57.8M
| $756K | ﹤0.01% |
120,000
-66,961
| -36% | -$439K |
|
|
OPRA
2696
Opera Ltd
OPRA
$1.82B
| $755K | ﹤0.01% |
120,000
+36,400
| +44% | +$183K |
|
2697
Schwab US Mid-Cap ETF
SCHM
$15.4B
| $755K | ﹤0.01% |
34,500
-14,700
| -30% | -$322K |
|
2698
iShares MSCI South Africa ETF
EZA
$560M
| $752K | ﹤0.01% |
+17,728
| New | +$726K |
|
2699
Lexicon Pharmaceuticals
LXRX
$1.03B
| $751K | ﹤0.01% |
393,285
-88,090
| -18% | -$187K |
|
2700
NI Holdings
NODK
$312M
| $750K | ﹤0.01% |
56,491
-7,000
| -11% | -$95.3K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.